Tags: Drug.
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.Mogamulizumab was developed by Kyowa Hakko Kirin Co. Ltd. It has also been licensed to Amgen for development as a therapy for Asthma.